HIV researcher David Ho has a new line of attack on SARS-CoV-2, and his fledgling startup is gunning for the clinic

Max Gelman

Senior Editor

The famed AIDS researcher David Ho started off the Covid-19 pandemic working to develop an antibody against the SARS-CoV-2 virus, but now he’s behind a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

HIV researcher David Ho has a new line of attack on SARS-CoV-2, and his fledgling startup is gunning for the clinic

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

HIV re­searcher David Ho has a new line of at­tack on SARS-CoV-2, and his fledg­ling start­up is gun­ning for the clin­ic

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

HIV researcher David Ho has a new line of attack on SARS-CoV-2, and his fledgling startup is gunning for the clinic